|Articles|January 19, 2021
Screening developability and pre-formulation by HT-DLS
Author(s)Wyatt Technology
Assessing a drug candidate early in discovery and development minimizes the risk of costly downstream failure. This white paper illustrates the application of automated DLS for aggregation and stability investigations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
5
